Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma

Next Previous
Trial Profile

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ExoSTING (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Head and neck cancer; Male breast cancer; Skin cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Codiak BioSciences

Most Recent Events

  • 07 Feb 2023 Status changed from active, no longer recruiting to completed.
  • 29 Aug 2022 Planned End Date changed from 1 Dec 2022 to 31 Dec 2022.
  • 29 Aug 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top